Picture Swiss Biotech Association LSUS Global Village 2025 Basel 650x100px

Organisation › Details

Seagen (Group)

https://www.seagen.com

LinkedIn: https://www.linkedin.com/company/seattle-genetics

Seagen Inc. is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California , Canada , Switzerland and the European Union. *

	Start	2020-10-08 renamed
	Group	Pfizer (Group)
	Predecessor	Seattle Genetics Inc. (Nasdaq: SGEN)
	Industry	BIOTECH
	Person	Siegall, Clay B. (SeattleGenetics 200512 CEO)

	Region	Bothell, WA
	Country	United States (USA)
	Street	21717 30th Drive S.E. Building 3
	City	98021 Bothell, WA
	Tel	+1-425-527-4000
		Address record changed: 2024-01-05

Basic data	Employees	n. a.
	Currency	USD
	Annual sales	22,420,000 (revenue, consolidated (2007) 2007-12-31)
	Profit	-48,932,000 (2007-12-31)
	Cash	111,361,000 (2007-12-31)

		* Document for »About Section«: Seagen Inc.. (10/8/20). "Press Release: Seattle Genetics, Inc. Announces Corporate Name Change to Seagen Inc.". Bothell, WA.

		Record changed: 2024-06-19

Picture EBD Group BIO-Europe Spring 2025 Milan to 14 Mar 650x200px

More documents for Pfizer (Group)

[1] Organon & Co.. (9/3/24). "Press Release: Organon Appoints Daniel Karp as Executive Vice President, Corporate Development". Jersey City, NJ....
[2] BioNTech SE. (8/22/24). "Press Release: Pfizer and BioNTech Receive U.S. FDA Approval & Authorization for Omicron KP.2-adapted COVID-19 Vaccine". New York, NY & Mainz....
[3] BioNTech SE. (8/16/24). "Press Release: Pfizer and BioNTech Provide Update on mRNA-based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age". New York, NY & Mainz....
[4] BioNTech SE. (8/5/24). "Press Release: BioNTech Announces Second Quarter 2024 Financial Results and Corporate Update". Mainz....
[5] Pfizer Inc.. (4/26/24). "Press Release: U.S. FDA Approves Pfizer’s Beqvez (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B". New York, NY....
[6] Mission Therapeutics Ltd.. (3/14/24). "Press Release: Mission Therapeutics Raises £25.2 Million to Progress Clinical Candidates in the Area of Mitophagy". Cambridge....
[7] J.P. Morgan Asset Management. (2/27/24). "Press Release: J.P. Morgan Life Sciences Private Capital Team Adds Healthcare Veteran and Past Seagen CEO David Epstein to Advisory Board". New York, NY....
[8] Ginkgo Bioworks Inc.. (9/27/23). "Press Release: Ginkgo Bioworks Announces Multi-Target RNA Discovery Collaboration with Pfizer". Boston, MA....
[9] AstraZeneca plc. (9/20/23). "Press Release: Alexion Completes Purchase and Licence Agreement for Early-stage Rare Disease Gene Therapy Portfolio from Pfizer"....
[10] CureVac N.V.. (5/19/23). "Press Release: CureVac Announces Developments in Patent Litigation with Pfizer/BioNTech". Tübingen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]